Journal of Bioterrorism and Biosafety

Dr. Robert R. Redfield is currently working as a professor and as IHV Associate Director and Director of the Division of Clinical Care and Research, at University of Maryland, Baltimore. He received many honors and awards in his career. He published many articles in international journals. 

Dr. Robert R. Redfield research is mainly focused on clinical research and clinical care of chronic human viral infections, especially HIV. His dominant area of research interest is the development of novel biological approaches to the treatment of chronic viral pathogens with a particular focus of targeting host cell pathways for their therapeutic potential. Several novel areas under active translation investigation include: targeting key biochemical pathways of nucleotide biosynthesis to enhance activity of specific antiretroviral medication; targeting cell activation with specific cell cycles as aprimary treatment target; use of G1 cell cycle agents to down regulate expression of key HIV host cell receptors; use of G1 cell cycles to enhance antiviral activity of HIV entry inhibitors; and the use of HIV specific proteins as therapeutic vaccines.